Abstract: Described herein are compositions comprising, and methods for using, biocompatible cold slurries and methods of administering the same to provide reversible inhibition of peripheral nerves in a subject in need thereof.

Abstract: One aspect of the invention provides a slurry comprising: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible surfactant. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; a biocompatible surfactant; and a foam comprising a plurality of gas bubbles. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible excipient. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a lipolytic agent.

Abstract: Described herein are compositions comprising, and methods for using, biocompatible cold slurries and methods of administering the same to provide reversible inhibition of peripheral nerves in a subject in need thereof.

Abstract: Described herein are compositions comprising, and methods for using, biocompatible cold slurries and methods of administering the same to provide reversible inhibition of peripheral nerves in a subject in need thereof.

Abstract: The present disclosure provides systems and method for medical ice slurry production. In particular, systems and methods are provided for medical ice slurry production that enable an end user to produce and deliver a sterile medical ice slurry at the point of care.

Abstract: A method for treating vascular diseases is provided. The method includes fabricating a sterile ice slurry including water and ice particles, cooling the sterile ice slurry to a predetermined temperature, and injecting the sterile ice slurry into a desired tissue region. The desired tissue region includes perivascular adipose tissue.

Abstract: Disclosed herein are methods that allow for efficient delivery of one or more agents to one or more peripheral nerves or the central nervous system by reversibly breaking down one or more of the perineurial (e.g., nerve-tissue), endoneurial (e.g., blood-nerve or “BNB”), Schwann cell, and blood-brain barriers.

Abstract: The present disclosure provides systems and method for medical ice slurry production. In particular, systems and methods are provided for medical ice slurry production that enable an end user to produce and deliver a sterile medical ice slurry at the point of care.

Abstract: The invention of the present disclosure provides a method for treating a viral infection in a recipient subject suffering from or at risk of a viral infection including administering to the recipient subject a pharmaceutical composition comprising a therapeutic amount of superactivated cytokine killer T cells (SCKTCs) and a pharmaceutically acceptable carrier, and mobilizing an immune response of the recipient subject to the viral pathogen. When tested in vitro, the SCKTCs are characterized by a predominant production of TH1 dominant cytokines including IFN-?; an IFN-?:IL-4 ratio of at least 500:1; and at least 50% killing of target A549 cells at an effector:target ratio of 20:1.

Abstract: A method for treating vascular diseases is provided. The method includes fabricating a sterile ice slurry including water and ice particles, cooling the sterile ice slurry to a predetermined temperature, and injecting the sterile ice slurry into a desired tissue region. The desired tissue region includes perivascular adipose tissue.

Abstract: Systems and methods for the use of cooling to trigger desirable effects of increased vasculature and/or development of new collagen in biological tissue are provided. In particular, the systems and methods provide a cooling treatment system configured to provide bulk or fractionated cooling at either at ablative temperatures or intermediary remodeling temperatures to promote tissue remodeling by inducing increased vasculature and/or the formation of new collagen.

Abstract: A method for treating vascular diseases is provided. The method includes fabricating a sterile ice slurry including water and ice particles, cooling the sterile ice slurry to a predetermined temperature, and injecting the sterile ice slurry into a desired tissue region. The desired tissue region includes perivascular adipose tissue.

Abstract: The present disclosure relates to compositions and methods for manufacturing biomaterials that form flowable and injectable cold slurries. More particularly, the present disclosure relates to a composition containing a plurality of liposomes where the encapsulated internal liposomal media and external liposomal media have different freezing points.

Abstract: The present disclosure provides, in part, a priming and boosting vector-based platform to develop vaccines against viral pathogens that is tailored to elicit a broad T cell response targeting conserved viral epitopes while including helper T cell (TH) epitopes and an adjuvant to achieve a balanced immune response consisting of both cellular immunity, coupled with a broad neutralizing antibody response in the design of a candidate universal vaccine to HIV or a human coronavirus, e.g., SARS-CoV-2. The universal vaccines are prepared against an immunogen of an infectious pathogenic virus comprising at least one nucleic acid polynucleotide comprising an open reading frame encoding at least one polypeptide antigen or an immunogenic fragment thereof, wherein the polypeptide antigen, or the immunogenic fragment thereof, comprises a conserved internal protein that is enriched in T cell recognition antigens.

Abstract: A method for treating vascular diseases is provided. The method includes fabricating a sterile ice slurry including water and ice particles, cooling the sterile ice slurry to a predetermined temperature, and injecting the sterile ice slurry into a desired tissue region. The desired tissue region includes perivascular adipose tissue.

Abstract: A treatment system can include a channel generation system configured to expose an infected region of a target tissue with a laser beam traveling along an optical axis and focused at a focal volume located in or adjacent to the target tissue. The laser beam can have a wavelength ranging from about 100 nm to about 400 nm. The laser beam can be configured to generate at least a first channel in the infected region. The treatment system can also include a detection system configured to detect a first radiation generated by one or more of (i) the target tissue, (ii) a fungi coupled to the infected region in the target tissue, and (iii) an adjacent tissue located proximal to the target tissue as a result of interaction with the laser beam. The treatment system can also include a delivery system configured to deposit an active treatment agent in the at least first channel.

Abstract: The present disclosure is directed to systems and methods that removing exogenous particles from a target region of the skin of a patient. The systems and methods can employ dermal lavage to remove the exogenous particles from the target region. In some instances, the exogenous particles can be residual tattoo ink after a tattoo removal process. A conduit can be sized and dimensioned for insertion into or around the target region to inject an irrigation fluid that defines an irrigation area. The exogenous particles can be suspended in the irrigation fluid. A device can be configured to form one or more channels in the irrigation area so that the exogenous particles are removable from the irrigation area.

Abstract: Systems and methods for a laser-assisted topical treatment of nail fungal infections are provided. The laser-assisted topical treatment includes a laser that is configured to output a beam that penetrates the infected nail and creates a channel therethrough. The laser-assisted topical treatment further includes a treatment agent comprising a vehicle and a drug. The treatment agent is applied to an exterior surface of the infected nail so that the treatment agent may flow into the channel.

Abstract: Systems and methods for a laser-assisted topical treatment of nail fungal infections are provided. The laser-assisted topical treatment includes a laser that is configured to output a beam that penetrates the infected nail and creates a channel therethrough. The laser-assisted topical treatment further includes a treatment agent comprising a vehicle and a drug. The treatment agent is applied to an exterior surface of the infected nail so that the treatment agent may flow into the channel.

Abstract: The present disclosure is directed to systems and methods that removing exogenous particles from a target region of the skin of a patient. The systems and methods can employ dermal lavage to remove the exogenous particles from the target region. In some instances, the exogenous particles can be residual tattoo ink after a tattoo removal process. A conduit can be sized and dimensioned for insertion into or around the target region to inject an irrigation fluid that defines an irrigation area. The exogenous particles can be suspended in the irrigation fluid. A device can be configured to form one or more channels in the irrigation area so that the exogenous particles are removable from the irrigation area.